Cancers · 2021 · 18 citations · 42 references
MedicineOncologyPathologyCancer ImmunologyMetastasisTumor ImmunologyCancer ImmunotherapyImmuno-oncology BiomarkersMetastatic Breast CancerTumor AntigensTumor-associated AntigensTumor-infiltrating LymphocytesConsensusImmune Biomarkers In CancerInterobserver Agreement In StagingPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerTnm Staging SystemTriple-negative Breast Cancer Therapy
Patients with advanced triple-negative breast cancer (TNBC) benefit from treatment with atezolizumab, provided that the tumor contains ≥1% of PD-L1/SP142-positive immune cells. Numbers of tumor-infiltrating lymphocytes (TILs) vary strongly according to the anatomic localization of TNBC metastases. We investigated inter-pathologist agreement in the assessment of PD-L1/SP142 immunohistochemistry and TILs. Ten pathologists evaluated PD-L1/SP142 expression in a proficiency test comprising 28 primary TNBCs, as well as PD-L1/SP142 expression and levels of TILs in 49 distant TNBC metastases with various localizations. Interobserver agreement for PD-L1 status (positive vs. negative) was high in the proficiency test: the corresponding scores as percentages showed good agreement with the consensus diagnosis. In TNBC metastases, there was substantial variability in PD-L1 status at the individual patient level. For one in five patients, the chance of treatment was essentially random, with half of the pathologists designating them as positive and half negative. Assessment of PD-L1/SP142 and TILs as percentages in TNBC metastases showed poor and moderate agreement, respectively. Additional training for metastatic TNBC is required to enhance interobserver agreement. Such training, focusing on metastatic specimens, seems worthwhile, since the same pathologists obtained high percentages of concordance (ranging from 93% to 100%) on the PD-L1 status of primary TNBCs.
42
The Measurement of Observer Agreement for Categorical Data
J. Richard Landis, Gary G. Koch · Biometrics · 1977 · 78.9K citations · Full text
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +16
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text